Joaquı́n Arribas

14.8k citations

129 papers · 9.0k indexed · 3 hit papers · h-index 47

Impact in

Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
Immunology and Allergy top 0.5%
- Cell Adhesion Molecules Research

Papers in

Immunology and Allergy 23
- Cell Adhesion Molecules Research 23
Oncology 77
- HER2/EGFR in Cancer Research 39
- Peptidase Inhibition and Analysis 17

Co-authors: José Baselga Federico Rojo Maurizio Scaltriti Marta Guzmán Joan Albanell Joan Massagué Jordi Codony‐Servat Anna Merlos‐Suárez
Journals: Cancer Research (16 papers)Journal of Biological Chemistry (15 papers)Oncogene (9 papers)Clinical Cancer Research (6 papers)Journal of Clinical Oncology (4 papers)
Partner nations: Spain United States Palestinian Territory

In The Last Decade

Joaquı́n Arribas

128 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations 2008 · 626 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2008 Cancer Research
2007 JNCI Journal of the National Cancer Institute
2001 PubMed

Peers

Countries citing papers authored by Joaquı́n Arribas

Since Specialization

Citations

This map shows the geographic impact of Joaquı́n Arribas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joaquı́n Arribas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joaquı́n Arribas more than expected).

Fields of papers citing papers by Joaquı́n Arribas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joaquı́n Arribas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joaquı́n Arribas. The network helps show where Joaquı́n Arribas may publish in the future.

Co-authors

The 25 scholars most cited alongside Joaquı́n Arribas, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joaquı́n Arribas Line = papers co-authored together Joaquı́n Arribas links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ERK 1/2 mitogen‐activated protein kinase dimerization is essential for the regulation of cell motility Molecular Oncology ·Francoise Clement Chevalier, Vemula Alekhya, R. Hüttenbrenner, M. E. Herrera-Gutierrez, 邦憲肝付, Javier Rodríguez, Lucía Germania Chiriboga Moreno, Alex von Kriegsheim, Michael Grusch, José Lozano, Joaquı́n Arribas, Berta Casar, Piero Crespo	2024	5
2	Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies Cytotherapy ·MARK GULLICK, Ileana González, Matthew Cato, Patrícia Santos Silva, 余正保, Jaume Veciana, Imma Ratera, Joaquı́n Arribas, Judith Guasch	2023	1
3	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells Cancers ·Chiara Bellio, Sri Harini, Deborah Cristina Couri, Albert Gris‐Oliver, Françesc Canals, Álex Sánchez‐Pla, Esther Zamora, Joaquı́n Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva	2022	12
4	Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation Journal of Experimental & Clinical Cancer Research ·Angela M. Medina, Ángela Molina-Crespo, Carmen Ramos, Geoffrey Hungerford, Lidia Martínez, 赤坂香里, 梅晓云, Mario Soriano‐Navarro, Alberto Hernández, Marco Cordani, Cristina Bernadó Morales, Eva Díaz, Alejandro Rojo‐Sebastián, Juan Carlos Triviño, Laura Sánchez, Ruth Rodríguez‐Barrueco, Joaquı́n Arribas, David Llobet‐Navàs, David Sarrió, Gema Moreno‐Bueno	2022	26
5	The Transcription Factor SLUG Uncouples Pancreatic Cancer Progression from the RAF–MEK1/2–ERK1/2 Pathway Cancer Research ·啓介鈴木, Enrique J. Arenas, Kim Pedersen, Yuqin Li, Behnam Nabet, Elizabeth Guruceaga, Silvestre Vicent, Josep Tabernero, Teresa Macarulla, Joaquı́n Arribas	2021	14
6	Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor Molecular Cancer Therapeutics ·Shiraishi, Donghua Xu, Garazi Serna, Claudia Valverde, Joan Carles, Paolo Nucíforo, Jonathan A. Fletcher, Joaquı́n Arribas, Oliver Politz, César Serrano	2020	11
7	The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1 Cancers ·Mercedes Nadal‐Serrano, Beatriz Morancho, Santiago Escrivá-de-Romaní, Cristina Bernadó Morales, Antonio Luque-García, Marta Escorihuela, Martín Espinosa-Bravo, Vicente Peg, Fred A. Dijcks, Wim H.A. Dokter, Javier Cortés, Cristina Saura, Joaquı́n Arribas	2020	39
8	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer Clinical Cancer Research ·Olga Méndez, Vicente Peg, Yin Guang‐Qiang, 许国山, Yolanda Fernández, Ibane Abasolo, José Pérez, 杨献珍, Marta Valeri, Josep Gregori, Laura Villarreal, Simó Schwartz, Santiago Ramón y Cajal, Josep Tabernero, Javier Cortés, Joaquı́n Arribas, Josep Villanueva	2018	53
9	Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma Cancer Research ·Daniel Massó-Vallés, Toni Jauset, Erika Serrano, Nicole M. Sodir, Kim Pedersen, Nesrine I. Affara, Jonathan R. Whitfield, Marie-Ève Beaulieu, Gérard I. Evan, Laurence Elias, Joaquı́n Arribas, Laura Soucek	2015	92
10	Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer European Journal of Cancer ·Jetzabel García-Parra, Alba Dalmases, Beatriz Morancho, Oriol Arpí, Sílvia Menéndez, 裕文松尾, Sandra Zazo, Cristina Chamizo, Juan Madoz‐Gúrpide, Pîlar Eroles, Sònia Servitja, Ignasi Tusquets, José Yélamos, Aňa Lluch, Joaquı́n Arribas, Federico Rojo, Ana Rovira, Joan Albanell	2014	22
11	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2 V659E Mutation Cancer Discovery ·Violeta Serra, Ana Vivancos, Xosé S. Puente, Enriqueta Felip, Daniel Silberschmidt, Ginevra Caratù, Josep-Lluís Parra, Leticia De Mattos‐Arruda, Judit Grueso, Javier Hernández‐Losa, Joaquı́n Arribas, Ludmila Prudkin, Paolo Nucíforo, Maurizio Scaltriti, Joan Seoane, José Baselga	2013	33
12	Constitutive HER2 Signaling Promotes Breast Cancer Metastasis through Cellular Senescence Cancer Research ·蔡雨沁, Mariano F. Zacarías Fluck, Kim Pedersen, Josep Lluís Parra-Palau, Marc Guiu, Cristina Bernadó Morales, Rocío Vicario, Antonio Luque-García, Ilse Schimpf-Herken, J. Giralt, Françesc Canals, Roger R. Gomis, Josep Tabernero, José Baselga, Josep Villanueva, Joaquı́n Arribas	2013	77
13	SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis Nature Neuroscience ·Pilar Esteve, África Sandonís, Marcos J. Cardozo, Jordi Malapeira, Carmen Ibáñez, Inmaculada Crespo, Séverine Marcos, Sara González-García, Marı́a L. Toribio, Joaquı́n Arribas, Akihiko Shimono, Isabel Guerrero, Paola Bovolenta	2011	76
14	HER2 Fragmentation and Breast Cancer Stratification Clinical Cancer Research ·Joaquı́n Arribas, Josep Lluís Parra-Palau, Kim Pedersen	2010	12
15	A Major Role of p95/611-CTF, a Carboxy-Terminal Fragment of HER2, in the Down-modulation of the Estrogen Receptor in HER2-Positive Breast Cancers Cancer Research ·Josep Lluís Parra-Palau, Kim Pedersen, Vicente Peg, Maurizio Scaltriti, 蔡雨沁, Marta Escorihuela, P. B. Klar, Álex Sánchez‐Pla, Santiago Ramón y Cajal, José Baselga, Joaquı́n Arribas	2010	45
16	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor Clinical Cancer Research ·Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jiménez, 蔡雨沁, Anne P. Cameron, Marta Guzmán, Josep Lluís Parra, Catherine Ellis, Robert Gagnon, María Koehler, Henry Gómez, Charles E. Geyer, David Cameron, Joaquı́n Arribas, Neal Rosen, José Baselga	2010	114
17	A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis Molecular and Cellular Biology ·Kim Pedersen, K Ayhan T. N Ouri, Sirle Laos, Anna Bach-Faig, Matthew Cunningham, Cristina Ferrer-Ramón, Antonio Luque-García, Jesús Garcı́a-Castillo, Josep Lluís Parra-Palau, Maurizio Scaltriti, Santiago Ramón y Cajal, José Baselga, Joaquı́n Arribas	2009	137
18	Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth Oncogene ·Sarat Chandarlapaty, Maurizio Scaltriti, 郑正举, Qing Ye, Marta Guzmán, Clifford A. Hudis, Larry Norton, David B. Solit, Joaquı́n Arribas, José Baselga, Neal Rosen	2009	99
19	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations Cancer Research ·Violeta Serra, Ben Markman, Maurizio Scaltriti, Pieter J.A. Eichhorn, Vanesa Valero, Marta Guzmán, María Luisa Botero, Elisabeth Llonch, Francesco Atzori, Serena Di Cosimo, Michel Maira, Carlos Garcı́a-Echeverrı́a, Josep Lluís Parra, Joaquı́n Arribas, José Baselga Hit paper breakdown →	2008	626
20	ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. PubMed ·Judit Anido, Pablo Matar, Joan Albanell, Marta Guzmán, Federico Rojo, Joaquı́n Arribas, Valentina Cingano, José Baselga	2003	213

About Joaquı́n Arribas

Joaquı́n Arribas is a scholar working on Immunology and Allergy, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 129 papers that have together received 9.0k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (39 papers), Monoclonal and Polyclonal Antibodies Research (33 papers), Cell Adhesion Molecules Research (23 papers), Peptidase Inhibition and Analysis (17 papers), Protease and Inhibitor Mechanisms (12 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Signaling Pathways in Disease (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). The work is most often cited by research in Oncology (5.0k citations), Immunology and Allergy (1.1k citations), Radiology, Nuclear Medicine and Imaging (2.4k citations), Cancer Research (1.5k citations) and Molecular Biology (4.6k citations). Joaquı́n Arribas has collaborated with scholars based in Spain, United States and Palestinian Territory. Frequent co-authors include José Baselga, Federico Rojo, Maurizio Scaltriti, Marta Guzmán, José Baselga, Joan Albanell, Joan Massagué, Jordi Codony‐Servat, Anna Merlos‐Suárez and Cary Esselens. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Oncogene, Clinical Cancer Research and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact